Time to Reconsider Atricure Inc (NASDAQ:ATRC) After More Short Sellers?

November 10, 2018 - By Adrian Mccoy

AtriCure, Inc. (NASDAQ:ATRC) Logo

Investors sentiment increased to 1.38 in Q2 2018. Its up 0.60, from 0.78 in 2018Q1. It improved, as 7 investors sold AtriCure, Inc. shares while 30 reduced holdings. 13 funds opened positions while 38 raised stakes. 28.28 million shares or 5.97% more from 26.69 million shares in 2018Q1 were reported.
First Light Asset Management Lc stated it has 5.81% of its portfolio in AtriCure, Inc. (NASDAQ:ATRC). Wasatch Advsr holds 0.12% or 367,739 shares in its portfolio. Bluemountain Cap Lc accumulated 14,904 shares. Loomis Sayles Com L P has 0.05% invested in AtriCure, Inc. (NASDAQ:ATRC) for 921,543 shares. 17,312 are held by State Board Of Administration Of Florida Retirement System. Utd Cap Financial Advisers Ltd Limited Liability Company reported 20,004 shares stake. Swiss Bank accumulated 56,900 shares or 0% of the stock. Northern Tru has 0% invested in AtriCure, Inc. (NASDAQ:ATRC) for 442,001 shares. Goldman Sachs Group has 127,943 shares for 0% of their portfolio. Invesco Ltd has 17,374 shares for 0% of their portfolio. Neuberger Berman Gru Ltd Liability Company has 760,526 shares. Ameriprise stated it has 0% in AtriCure, Inc. (NASDAQ:ATRC). 37,700 are owned by New York State Common Retirement Fund. Bnp Paribas Arbitrage Sa has invested 0% in AtriCure, Inc. (NASDAQ:ATRC). State Street Corp holds 0% in AtriCure, Inc. (NASDAQ:ATRC) or 747,199 shares.

Since May 15, 2018, it had 0 buys, and 3 insider sales for $265,730 activity. Collar Mark A sold 2,090 shares worth $52,250.

The stock of Atricure Inc (NASDAQ:ATRC) registered an increase of 1.78% in short interest. ATRC’s total short interest was 2.10M shares in November as published by FINRA. Its up 1.78% from 2.06M shares, reported previously. With 152,500 shares average volume, it will take short sellers 14 days to cover their ATRC’s short positions. The short interest to Atricure Inc’s float is 6.89%.

The stock decreased 2.64% or $0.89 during the last trading session, reaching $32.76. About 151,497 shares traded. AtriCure, Inc. (NASDAQ:ATRC) has risen 68.55% since November 10, 2017 and is uptrending. It has outperformed by 52.93% the S&P500.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company has market cap of $1.26 billion. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It currently has negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

Among 3 analysts covering Atricure (NASDAQ:ATRC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Atricure had 5 analyst reports since June 18, 2018 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Wednesday, June 27 with “Buy”. Needham maintained AtriCure, Inc. (NASDAQ:ATRC) rating on Monday, June 18. Needham has “Buy” rating and $3200 target. Canaccord Genuity maintained AtriCure, Inc. (NASDAQ:ATRC) on Wednesday, June 27 with “Buy” rating. Needham maintained AtriCure, Inc. (NASDAQ:ATRC) on Wednesday, June 27 with “Buy” rating. Canaccord Genuity maintained AtriCure, Inc. (NASDAQ:ATRC) on Tuesday, October 9 with “Buy” rating.

More news for AtriCure, Inc. (NASDAQ:ATRC) were recently published by: Businesswire.com, which released: “AtriCure to Present at the Piper Jaffray 30” on November 08, 2018. Seekingalpha.com‘s article titled: “AtriCure’s (ATRC) CEO Mike Carrel on Q3 2018 Results – Earnings Call Transcript” and published on November 03, 2018 is yet another important article.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>